Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant

Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant.

An pro consultative panel recommended on Tuesday that Contrave, a novel weight-loss pill that combines an antidepressant with an anti-addiction medication, be approved by the US Food and Drug Administration. The 13-7 opinion in favor of Contrave came amid agency concerns that the opiate might raise blood pressure in some patients and increase the risk of heart attacks and strokes surrounded by some users, according to the Associated Press tribulus. But panelists voted 11-8 earlier in the daylight that those potential health risks could be studied after Contrave was approved.

The FDA does not have to follow the advice of its advisory committees, but it typically does. The mechanism is expected to make a decision on Contrave by Jan 31, 2011, the wire worship reported. contrave is manufactured by orexigen therapeutics inc. In October, the FDA voted against approving two other weight-loss drugs, Arena Pharmaceuticals' lorcaserin and Vivus' Qnexa, because of protection concerns, according to the AP article source. Last July, a mull over funded by Orexigen and published in The Lancet found that Contrave helped users desquamate pounds when taken along with a in good diet and exercise.

People who took the drug for more than a year lost an average of 5 percent or more of body weight, depending on the administer used, the team said. However, the regimen did come with side effects, and about half of lucubrate participants dropped out before completing a year of treatment. Contrave is combination of two famed drugs, naltrexone (Revia, used to fight addictions) and the antidepressant bupropion (known by a numbers of names, including Wellbutrin).

The drug appears to boost weight loss by changing the workings of the body's important nervous system, the researchers said. The study enrolled men (15 percent) and women (85 percent) from around the country, ranging in adulthood from 18 to 65. They were all either rotund or overweightm, with high blood fat levels or high blood pressure.

The participants were told to nourishment less and exercise, and they were randomly assigned to take a twice-daily placebo or a confederation of the two drugs at one of two levels. After 56 weeks, only about half (870) of the more than 1700 participants initially enrolled remained in the study. Almost half (48 percent) of those who took the highest portion of naltrexone dead 5 percent of their weight or more, while only 16 percent of those who took placebos did.

However, about 30 percent of those taking Contrave skilful nausea, the study authors say, and other incidental effects included headache, constipation, dizziness, vomiting and dry mouth. Still, Contrave may give citizenry struggling to lose weight a new option, the researchers contended.

The Lancet findings reiteration those of studies into other diet drugs such as Meridia, Xenical and Alli, said Lona Sandon, an aide-de-camp professor of clinical nutrition at the University of Texas Southwestern Medical Center in Dallas and spokeswoman for the American Dietetic Association. "When these are combined with a modestly reduced calorie diet, restrained amounts of bulk loss are achieved. One striking loathing to note is the study drop-out rate of 50 percent. This may have been due to side effects of medications, the happening that it is hard to stick to dietary changes for 56 weeks, or the fact that slow and only modest heft loss did not meet participant expectations".

Cynthia Sass, a New York City-based nutritionist and author, added that drugs Euphemistic pre-owned to treat addiction also appear to help with weight control, supporting "the general idea that food can be addictive for many people". An accompanying Lancet editorial noted that one charge is that blood pressure did not drop as much as expected in the higher weight-loss group go here. "More data are needed to get a better overall assessment of cardiovascular danger of this otherwise promising combination therapy for obesity," wrote Professor Arne Astrup, a nutrition pundit at the University of Copenhagen, Denmark.

tag : contrave weight percent drugs study blood effects participants pressure

Post a comment

Private comment



Dr. Alejandra Falto

Новые записи
Новые комментарии
Новые трэкбэки
Архив по месяцам
Форма поиска
RSS ссылка
Формуляр приглашения в блог-друзья

Добавить автора в блог-друзья